January 2024 in “Wiadomości Lekarskie” Pre-surgical embolization and a two-stage resection improve outcomes for rare sacral tumors.
January 2024 in “Wiadomości Lekarskie” A multidisciplinary approach is crucial for managing Silver-Russell syndrome effectively.
January 2024 in “Wiadomości Lekarskie” Countries should improve sex education, access to contraception, and legal abortion options.
January 2024 in “Wiadomości Lekarskie” Rhabdomyosarcoma is the most common head and neck cancer in children, requiring complex treatment.
January 2024 in “Wiadomości Lekarskie” Comprehensive treatment improved hearing in 89.7% of soldiers with blast-induced hearing loss.
January 2024 in “Wiadomości Lekarskie” Ancient immune and signaling pathways still regulate blood cell development.
January 2024 in “Wiadomości Lekarskie” Virtual surgical planning improves efficiency, coordination, and precision in complex surgeries.
January 2023 in “Wiadomości Lekarskie” Local antibiotic therapy can effectively treat root canal infections.
1 citations
,
August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
New insights into cell communication in psoriasis suggest innovative drug treatments.
1 citations
,
June 2025 in “Frontiers in Bioengineering and Biotechnology” Glycopeptide hydrogels are promising for tissue repair, drug delivery, and healing due to their multifunctional properties.
19 citations
,
September 2019 in “EMBO molecular medicine” Blocking TSLP reduces skin inflammation and cell overgrowth in psoriasis.
6 citations
,
July 2018 in “Scientific Reports” Methamphetamine affects gene expression in rat whisker follicles, with key genes linked to addiction.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
9 citations
,
January 2020 in “Skin appendage disorders” Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
July 2024 in “Journal of Investigative Dermatology” 10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
1 citations
,
April 2024 in “Journal of Autoimmunity” Interleukin-15 can help hair growth and protect hair follicles.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.